Advisor Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Advisor Group’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-452	Closed	-$2K	–	5546
2019 Q3	$2K	Buy	452 +439	+3,377%	+$2.41K	﹤0.01%	5042
2019 Q2	$0	Buy	+13	New	+$124	﹤0.01%	5463
2018 Q3	–	Sell	-502	Closed	-$8K	–	5301
2018 Q2	$8K	Sell	502 -6	-1%	-$105	﹤0.01%	4202
2018 Q1	$9K	Buy	508 +260	+105%	+$5.07K	﹤0.01%	4169
2017 Q4	$5K	Hold	248	–	–	﹤0.01%	4439
2017 Q3	$10K	Sell	248 -43	-15%	-$1.35K	﹤0.01%	4001
2017 Q2	$9K	Buy	291 +76	+35%	+$2.37K	﹤0.01%	4009
2017 Q1	$8K	Buy	215 +29	+16%	+$1.28K	﹤0.01%	3931
2016 Q4	$9K	Hold	186	–	–	﹤0.01%	3688
2016 Q3	$10K	Buy	186 +39	+27%	+$1.86K	﹤0.01%	3573
2016 Q2	$6K	Buy	+147	New	+$6.39K	﹤0.01%	3732

Other funds holding FPRX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisor Group's FPRX Position: Q4 2019 in Review

Advisor Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2019, closing a stake of 452 shares — an estimated $2K sold.

Advisor Group first reported a position in FPRX in Q2 2016 and held it in 11 quarters. The position peaked at $10K in Q3 2017. 94 funds tracked by Wall St. Rank hold FPRX as of Q4 2019.

Advisor Group reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Advisor Group sold 452 Five Prime Therapeutics, Inc. shares in Q4 2019, an estimated $2K.
Advisor Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 11 quarters.
Advisor Group's Five Prime Therapeutics, Inc. position peaked at $10K in Q3 2017.
94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.